AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8534671 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily simvastatin, 20 mg daily simvastatin, Matching placebo
Number of subjects: 621
Study 2153194 — intervention group
Group type: COMPARATOR
Intervention: EVAC (etoposide, vincristine, doxorubicin, cyclophosphamide)
Number of subjects: 400
Study 2153194 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16/CDDP-VAC (etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide)
Number of subjects: 400
Study 2153194 — intervention group
Group type: COMPARATOR
Intervention: EVAC
Number of subjects: 400
Study 2153194 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16/CDDP-VAC
Number of subjects: 400
Study 389264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg daily) and soluble aspirin (3.6 g daily)
Number of subjects: 0
Study 389264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg daily) and soluble aspirin (2.4 g daily)
Number of subjects: 0
Study 389264 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (single drug period)
Number of subjects: 0
Study 389264 — intervention group
Group type: COMPARATOR
Intervention: Salicylate (single drug period)
Number of subjects: 0
Study 389264 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen administration
Number of subjects: 0
Study 389264 — intervention group
Group type: COMPARATOR
Intervention: Concurrent salicylate administration
Number of subjects: 0
Study 30931715 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-based intervention group
Number of subjects: 356
Study 30931715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 356
Study 28605609 — intervention group
Group type: EXPERIMENTAL
Intervention: VPRO (CHO 75 g, protein 25 g, vitamins D3 5000 IU, K2 1000 μg)
Number of subjects: 10
Study 28605609 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO (CHO 75 g, protein 25 g, no vitamins)
Number of subjects: 10
Study 28605609 — intervention group
Group type: COMPARATOR
Intervention: PLA (zero-calorie control drink)
Number of subjects: 10
Study 25528358 — intervention group
Group type: EXPERIMENTAL
Intervention: Active OIT
Number of subjects: 21
Study 25528358 — intervention group
Group type: COMPARATOR
Intervention: Active SLIT
Number of subjects: 21
Study 23883137 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) with job coach support
Number of subjects: 250
Study 23883137 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IPS support)
Number of subjects: 250
Study 22143664 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiographs with full dose
Number of subjects: 20
Study 22143664 — intervention group
Group type: COMPARATOR
Intervention: Digital radiographs with reduced dose
Number of subjects: 20
Study 22143664 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-resolution screen-film system
Number of subjects: 20
Study 19553594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine with frequency < monthly
Number of subjects: 27798
Study 19553594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine with frequency monthly
Number of subjects: 27798
Study 19553594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine with frequency >or= weekly
Number of subjects: 27798
Study 19553594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine with aura and frequency < monthly
Number of subjects: 27798
Study 19553594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine with aura and frequency >or= weekly
Number of subjects: 27798
Study 17224800 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐C based navigation (242 screws)
Number of subjects: 33
Study 17224800 — intervention group
Group type: COMPARATOR
Intervention: Non-navigation (236 screws)
Number of subjects: 33
Study 15309496 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical information alone (internists)
Number of subjects: 50
Study 15309496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest film alone (internists)
Number of subjects: 50
Study 15309496 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical information + Chest film (radiologists)
Number of subjects: 50
Study 15309496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest film (radiologists)
Number of subjects: 50
Study 15309496 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data access (radiologists)
Number of subjects: 50
Study 15309496 — intervention group
Group type: COMPARATOR
Intervention: Chest film (internists)
Number of subjects: 50
Study 11673321 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-and-error intentional learning task
Number of subjects: 0
Study 11673321 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental learning task
Number of subjects: 0
Study 9519371 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal spermatic vein from patients with varicocele testis
Number of subjects: 33
Study 9519371 — intervention group
Group type: COMPARATOR
Intervention: Left internal spermatic vein from controls (no varicocele testis)
Number of subjects: 33
Study 9519371 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal spermatic vein from patients (12 patients)
Number of subjects: 33
Study 7905549 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate low-fat diet (60:20% carbohydrate:fat)
Number of subjects: 14
Study 7905549 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate high-fat diet (20:60% carbohydrate:fat)
Number of subjects: 14
Study 7905549 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 14
Study 7905549 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 14
Study 7905549 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 14
Study 7905549 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 14
Study 3058919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (20 mg elemental zinc twice daily)
Number of subjects: 50
Study 3058919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 50
Study 3058919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (20 mg elemental zinc twice daily) in subjects with severe initial zinc depletion
Number of subjects: 50
Study 3058919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose) in subjects with severe initial zinc depletion
Number of subjects: 50
Study 3058919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 28429377 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training (OT) group, daily olfactory exposure for 5 months
Number of subjects: 91
Study 28429377 — intervention group
Group type: COMPARATOR
Intervention: Control group, daily Sudoku problems for 5 months
Number of subjects: 91
Study 27923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (approximately 48 µg/d as six Brazil nuts)
Number of subjects: 32
Study 27923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) capsules (four GTE capsules, 800 mg (‐)‐epigallocatechin‐3‐gallate)
Number of subjects: 32
Study 27923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Brazil nuts and GTE
Number of subjects: 32
Study 27923410 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 32
Study 25339632 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management (daily contact with monitoring centre using handheld PDA)
Number of subjects: 80
Study 25339632 — intervention group
Group type: COMPARATOR
Intervention: Usual care (follow‐up at the outpatient clinic)
Number of subjects: 80
Study 23525414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 81 mg daily
Number of subjects: 11
Study 23525414 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 11
Study 20686430 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time educational intervention (educational materials for dressing application attached to the manufacturer's dressing package)
Number of subjects: 139
Study 20686430 — intervention group
Group type: COMPARATOR
Intervention: Traditional wound care education
Number of subjects: 139
Study 20686430 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time educational intervention
Number of subjects: 139
Study 18334143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin-treated group (peroral administration of Maixuekang capsules)
Number of subjects: 262
Study 18334143 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole-treated group (peroral administration of dipyridamole)
Number of subjects: 262
Study 16608935 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 40
Study 16608935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol
Number of subjects: 40
Study 16608935 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy current smokers)
Number of subjects: 40
Study 16608935 — intervention group
Group type: COMPARATOR
Intervention: Control (ex-smokers with COPD)
Number of subjects: 40
Study 12911866 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% honey solution inhalation
Number of subjects: 46
Study 12911866 — intervention group
Group type: COMPARATOR
Intervention: Distill water inhalation
Number of subjects: 46
Study 12911866 — intervention group
Group type: COMPARATOR
Intervention: 10% dextrose inhalation
Number of subjects: 46
Study 11313239 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) donors treated with 5 to 7 days of filgrastim at a dose of 16 microg/kg/d and underwent 1 to 3 days of apheresis to obtain 5 x 10(6) CD34(+) cells per kilogram recipient weight.
Number of subjects: 69
Study 11313239 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow donors collected by standard harvest techniques and general or regional anesthesia.
Number of subjects: 69
Study 11313239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of donors (PBSC and marrow)
Number of subjects: 69
Study 9115157 — intervention group
Group type: EXPERIMENTAL
Intervention: 216 microg zoledronate
Number of subjects: 16
Study 9115157 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg zoledronate
Number of subjects: 16
Study 8195519 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (treatment group)
Number of subjects: 17
Study 8195519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spinal cord stimulation during initial 8 weeks)
Number of subjects: 17
Study 3298383 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Cystine and Pyridoxine Hydrochloride combination (in addition to classical post-operative treatment)
Number of subjects: 36
Study 3298383 — intervention group
Group type: COMPARATOR
Intervention: Classical post-operative treatment (control group)
Number of subjects: 36
Study 28988197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 642
Study 28988197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 642
Study 28988197 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 642
Study 28988197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg and 20 mg
Number of subjects: 642
Study 28988197 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 642
Study 28133772 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327 (40 mg)
Number of subjects: 180
Study 28133772 — intervention group
Group type: COMPARATOR
Intervention: EU-Humira (40 mg)
Number of subjects: 180
Study 28133772 — intervention group
Group type: COMPARATOR
Intervention: US-Humira (40 mg)
Number of subjects: 180
Study 25870124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B (Red yeast rice (Monakolin K 3.3 mg), Berberine 531.25 mg and leaf extract of Morus alba)
Number of subjects: 0
Study 25870124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination A (Policosanol, Red yeast rice (Monakolin K 3 mg), Berberine 500 mg, Astaxantine, Folic Acid and Coenzyme Q10)
Number of subjects: 0
Study 25870124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination A and Combination B
Number of subjects: 0
Study 25870124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B
Number of subjects: 0
Study 23188655 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-monitoring intervention
Number of subjects: 50
Study 23188655 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-monitoring intervention (helpful)
Number of subjects: 50
Study 23188655 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-monitoring intervention (not helpful)
Number of subjects: 50
Study 23188655 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (dietary information only)
Number of subjects: 50
Study 23188655 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (physical activity change)
Number of subjects: 50
Study 21248446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with oral sorafenib
Number of subjects: 35
Study 21248446 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab alone
Number of subjects: 35
Study 19064532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa treatment (150 mL twice a day, approximately 900 mg flavanols/d)
Number of subjects: 20
Study 19064532 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (approximately 28 mg flavanols/d)
Number of subjects: 20
Study 19064532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa treatment
Number of subjects: 20
Study 16210385 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 285
Study 16210385 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 285
Study 16210385 — intervention group
Group type: COMPARATOR
Intervention: Combination (Anastrozole + Tamoxifen)
Number of subjects: 285
Study 16210385 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole vs Tamoxifen
Number of subjects: 285
Study 12966380 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation program (staged range of motion and strengthening exercises from immediate postoperative day)
Number of subjects: 62
Study 12966380 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (3 weeks of immobilization using an abduction sling)
Number of subjects: 62
Study 10864051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone at a dose of 6 mg/m2 per day (standard risk) or 18 mg/m2 per day (high risk)
Number of subjects: 67
Study 10864051 — intervention group
Group type: COMPARATOR
Intervention: Prednisone at a dose of 40 mg/m2/d (standard risk) or 120 mg/m2/d (high risk)
Number of subjects: 67
Study 9768323 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right nasal strips
Number of subjects: 20
Study 29481452 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg·kg)
Number of subjects: 16
Study 29481452 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 16
Study 27548492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated olive oil
Number of subjects: 100
Study 27548492 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 100
Study 24793028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine dose escalation (2.4 g/day increase for 6 weeks)
Number of subjects: 52
Study 24793028 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued current dose of mesalamine)
Number of subjects: 52
Study 24793028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine dose escalation
Number of subjects: 52
Study 24793028 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with FC >200 μg/g
Number of subjects: 52
Study 23047713 — intervention group
Group type: EXPERIMENTAL
Intervention: Water drinking during exercise
Number of subjects: 10
Study 23047713 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (no water intake)
Number of subjects: 10
Study 19928596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum during a 16‐min concentration test
Number of subjects: 4
Study 19928596 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (control group)
Number of subjects: 4
Study 16803726 — intervention group
Group type: EXPERIMENTAL
Intervention: New personal protective eyewear
Number of subjects: 21
Study 16803726 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially aged personal protective eyewear
Number of subjects: 21
Study 16803726 — intervention group
Group type: COMPARATOR
Intervention: Control (no personal protective eyewear)
Number of subjects: 21
Study 15345600 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by clinicians with telephone support under supervision from a psychiatrist
Number of subjects: 405
Study 15345600 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 405
Study 11524326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block with 1.5% mepivacaine (40 mL) followed by a postoperative intraarticular infusion of 0.5% ropivacaine at 2 mL/h
Number of subjects: 40
Study 11524326 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block with 0.5% ropivacaine (40 mL) followed by a postoperative intraarticular infusion of 0.9% saline (placebo) at 2 mL/h
Number of subjects: 40
Study 9240590 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 85
Study 9240590 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 85
Study 8237931 — intervention group
Group type: EXPERIMENTAL
Intervention: iv nitroglycerin (150‐micrograms bolus)
Number of subjects: 27
Study 8237931 — intervention group
Group type: COMPARATOR
Intervention: iv metoclopramide (20‐mg bolus)
Number of subjects: 27
Study 3683816 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn pronunciation only
Number of subjects: 0
Study 3683816 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn both pronunciation and meaning
Number of subjects: 0
Study 3683816 — intervention group
Group type: COMPARATOR
Intervention: Learn meaning only
Number of subjects: 0
Study 3683816 — intervention group
Group type: COMPARATOR
Intervention: Learn nothing
Number of subjects: 0
Study 29997904 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-based cognitive behavioural intervention (ICBI)
Number of subjects: 56
Study 29997904 — intervention group
Group type: COMPARATOR
Intervention: Non-directive supportive therapy (NDST)
Number of subjects: 56
Study 28915797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component and environmental school-based intervention (16 months) including psychological counseling in groups, theoretical/practical nutrition workshops, and supervised physical education classes.
Number of subjects: 438
Study 28915797 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 353) participated in psychological counseling groups and theoretical/practical nutrition workshops for 6 months.
Number of subjects: 438
Study 26057703 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 367
Study 26057703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail clipping
Number of subjects: 367
Study 22934712 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwashed salvaged blood
Number of subjects: 22
Study 22934712 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed salvaged blood
Number of subjects: 22
Study 22934712 — intervention group
Group type: COMPARATOR
Intervention: Control samples (venous blood before surgery)
Number of subjects: 22
Study 20518170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Ximen (PC 4), Yinxi (HT 6), Xuehai (SP 10), Zhaohai (KI 6)) for 10 days
Number of subjects: 11
Study 20518170 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Carbamazepine) for 10 days
Number of subjects: 11
Study 18086927 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation with complete intraprocedural end points (voltage abatement, PV disconnection, exit-block pacing)
Number of subjects: 20
Study 18086927 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients who underwent redo ablation due to recurrences of atrial fibrillation)
Number of subjects: 20
Study 17028105 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity programme in nursery (three 30 minute sessions a week over 24 weeks) plus home based health education aimed at increasing physical activity through play and reducing sedentary behaviour.
Number of subjects: 545
Study 17028105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 545
Study 12742991 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day for 12 weeks)
Number of subjects: 97
Study 12742991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 12742991 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 97
Study 10695907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 0
Study 10695907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with propofol
Number of subjects: 0
Study 10695907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with thiopental
Number of subjects: 0
Study 9085015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexniguldipine (DNIG) 1-11 mg/kg/4h infusion
Number of subjects: 26
Study 9085015 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine 0.15 mg/kg
Number of subjects: 26
Study 9085015 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term infusion of DNIG (5 and 7 mg/kg/24h)
Number of subjects: 26
Study 9085015 — intervention group
Group type: EXPERIMENTAL
Intervention: DNIG infusion (5 and 7 mg/kg/4h)
Number of subjects: 26
Study 9085015 — intervention group
Group type: EXPERIMENTAL
Intervention: DNIG infusion
Number of subjects: 26
Study 8464320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine
Number of subjects: 45
Study 8464320 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 3465258 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 0
Study 3465258 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 0